Bausch + Lomb Co. (NYSE:BLCO) Shares Sold by Hara Capital LLC

Hara Capital LLC cut its holdings in shares of Bausch + Lomb Co. (NYSE:BLCO) by 66.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,161 shares of the company’s stock after selling 20,000 shares during the period. Hara Capital LLC’s holdings in Bausch + Lomb were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Clearline Capital LP grew its holdings in Bausch + Lomb by 136.8% during the second quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock worth $10,339,000 after acquiring an additional 411,404 shares during the period. Invenomic Capital Management LP purchased a new stake in Bausch + Lomb in the 1st quarter worth approximately $6,817,000. Whitebox Advisors LLC grew its stake in shares of Bausch + Lomb by 28.2% during the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company’s stock worth $22,447,000 after purchasing an additional 339,643 shares during the period. Rokos Capital Management LLP purchased a new position in shares of Bausch + Lomb during the 1st quarter valued at approximately $5,602,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Bausch + Lomb by 31.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company’s stock valued at $9,397,000 after purchasing an additional 153,000 shares during the period. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Price Performance

NYSE BLCO traded up $0.02 during trading hours on Thursday, hitting $19.85. 35,791 shares of the company’s stock traded hands, compared to its average volume of 568,647. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The firm’s 50-day moving average is $18.76 and its 200-day moving average is $16.56. Bausch + Lomb Co. has a 52-week low of $13.16 and a 52-week high of $21.69. The company has a market capitalization of $6.99 billion, a PE ratio of -18.89, a PEG ratio of 1.93 and a beta of 0.46.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.16 by $0.01. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.22 earnings per share. Equities analysts forecast that Bausch + Lomb Co. will post 0.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BLCO shares. Royal Bank of Canada lifted their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, October 22nd. Wells Fargo & Company increased their price target on Bausch + Lomb from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Stifel Nicolaus increased their target price on Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research report on Monday, September 23rd. Evercore boosted their price target on shares of Bausch + Lomb from $15.50 to $17.00 and gave the stock an “in-line” rating in a report on Thursday, August 1st. Finally, HC Wainwright lifted their target price on shares of Bausch + Lomb from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Bausch + Lomb has a consensus rating of “Moderate Buy” and an average price target of $20.91.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.